Introduction
The Global Chromatographic Separation Resins Market is moderately consolidated, with a distinct structure in each application area. In biopharmaceutical process chromatography, which accounts for 65.0% of 2025 demand, a small number of global suppliers hold leading positions because their resins are embedded in approved commercial manufacturing processes, and changing a qualified resin requires comparability studies and regulatory notification. This creates high switching costs and a recurring revenue base for incumbent suppliers. In food, industrial and research applications, the market is more fragmented, with regional manufacturers in China, Japan and elsewhere competing on price, local service and application expertise.
The nature of competition is innovation-led. Suppliers compete on dynamic binding capacity, alkaline stability, selectivity for difficult impurities, resin lifetime and productivity in continuous and intensified processes, supported by regulatory support files, supply assurance and technical service. Large life-science groups also compete through integrated downstream portfolios that combine resins with pre-packed columns, chromatography systems, filtration and process development services. In parallel, Chinese suppliers are expanding their portfolios and capacity, supported by the localisation of bioprocess supply chains, and are increasingly seeking export markets through distribution partnerships.
Key Player Positioning
The profiled companies are positioned below as leaders, challengers and niche players based on a qualitative assessment of portfolio breadth, installed base in commercial biologics processes, geographic reach, manufacturing capacity and recent strategic activity. Company revenues are stated as publicly reported, in the reporting currency of each company, for the latest available fiscal year.
Leaders
Cytiva (Danaher Corporation). Cytiva was formed when Danaher completed its acquisition of the GE Biopharma business in March 2020 and forms part of Danaher's Biotechnology segment, which reported sales of USD 7,293 million in FY2025 within total Danaher sales of USD 24,568 million. Cytiva holds the broadest process resin portfolio in the market, including the MabSelect Protein A family, Capto ion exchange and multimodal media, Sepharose resins and Superdex and Sephadex size exclusion media. Its strategy focuses on defending its large installed base in monoclonal antibody platform processes through higher-capacity, more alkali-stable resins such as MabSelect PrismA X, while strengthening supply resilience by expanding resin manufacturing in Uppsala, Sweden, and Muskegon, Michigan.
Merck KGaA, Darmstadt, Germany (MilliporeSigma in the U.S. and Canada). Merck's chromatography resins sit within the Process Solutions business of its Life Science sector, which reported FY2025 sales of EUR 3,785 million within Life Science sales of EUR 8,980 million and group sales of EUR 21,102 million. Its portfolio includes Eshmuno ion exchange and Protein A resins and Fractogel EMD ion exchange media. Merck strengthened its affinity capture offering by acquiring the chromatography business of JSR Life Sciences, including the Amsphere Protein A resins, with the transaction completed in April 2026. Its strategy is to position itself as a full downstream purification partner spanning resins, filtration, process development and viral-vector tools.
Thermo Fisher Scientific. Thermo Fisher supplies chromatography resins through its bioproduction business in the Life Sciences Solutions segment, which reported FY2025 revenue of USD 10,374 million within total revenue of USD 44,556 million. Its portfolio centres on POROS rigid polymeric beads for high-throughput ion exchange and affinity chromatography and on CaptureSelect affinity ligands, including resins for AAV serotypes, lentiviral vectors and antibody fragments. Its strategy combines high-flow resin technology with custom affinity ligands for bispecific antibodies and gene therapies, and broadening its bioproduction purification offering through acquisitions such as the Purification and Filtration business of Solventum, completed in September 2025.
Tosoh Corporation (Tosoh Bioscience). Tosoh reported consolidated net sales of JPY 1,019,917 million for the fiscal year ended March 2026, with its separation and purification media business operated through Tosoh Bioscience. Its portfolio includes TOYOPEARL process resins, spanning affinity, ion exchange, mixed-mode and hydrophobic interaction chemistries, TSKgel media and Ca++Pure-HA hydroxyapatite. Tosoh is pursuing a capacity-led strategy, investing approximately JPY 16 billion at its Nanyo complex and approximately JPY 14 billion in a new media plant at Yokkaichi, while expanding its presence in North America and Europe.
Challengers
Purolite (an Ecolab company). Ecolab acquired Purolite in December 2021, and its resins are reported within Ecolab's Life Sciences segment, which recorded FY2025 sales of USD 747.9 million within total Ecolab sales of USD 16,081.2 million. Purolite's Praesto range uses jetted agarose beads with a uniform particle size, and its affinity portfolio includes DurA Cycle and Purolite AP+50 Protein A resins, alongside Chromalite polymeric media for peptides and insulin. The company competes with incumbent Protein A suppliers on price and performance, using ligands co-developed with Repligen, and is expanding capacity in Wales and Pennsylvania and building application laboratories in the U.S. and Asia.
Bio-Rad Laboratories. Bio-Rad reported FY2025 net sales of USD 2,583.2 million, including USD 1,021.1 million from its Life Science segment, which houses its process chromatography business. Its portfolio comprises UNOsphere and Nuvia ion exchange and mixed-mode resins, CHT Ceramic Hydroxyapatite media and Foresight and Foresight Pro pre-packed columns. Bio-Rad focuses on polishing chemistries rather than Protein A capture, targeting aggregate and impurity removal in complex biologics, and is extending its GMP pre-packed column range to larger diameters to win commercial-scale processes.
Repligen Corporation. Repligen reported FY2025 revenue of USD 738.3 million. A long-standing supplier of Protein A ligands to resin manufacturers, the company has moved into finished resins through its AVIPure affinity resins for AAV, HiPer QA anion exchange media and Tantti DuloCore base beads, and supplies OPUS pre-packed columns. Its strategy is to combine in-house ligands and bead technology to address new modalities such as viral vectors, while co-developing monoclonal antibody capture resins with Ecolab's Purolite.
Niche and Regional Players
Mitsubishi Chemical Group. Mitsubishi Chemical Group reported sales revenue of JPY 3,704.0 billion for the fiscal year ended March 2026. Through its DIAION ion exchange and chromatographic separation resins, SEPABEADS synthetic adsorbents and MCI GEL media, the company is a significant supplier to sugar, food, pharmaceutical and industrial separations rather than to bioprocess affinity capture. Its strategy emphasises application expertise in large-scale industrial separations and investment in high-purity ion exchange resins.
Sunresin New Materials. Headquartered in Xi'an, China, Sunresin reported FY2025 revenue of CNY 2,786 million, of which its life sciences business contributed CNY 636 million. Beyond its large adsorption and ion exchange resin business, the company supplies Seplife chromatography media for vaccines, viral vectors, plasmid DNA and peptides, as well as solid-phase synthesis carriers. Its strategy is to leverage its industrial resin scale to grow in life sciences, supported by a planned life-science materials park in Pucheng and European distribution partnerships.
Suzhou Nanomicro Technology. Nanomicro, listed on the Shanghai STAR Market, reported FY2025 operating revenue of CNY 925 million. The company manufactures monodisperse silica and polymer microspheres for chromatography media, including UniMab Protein A, UniGel polymeric and UniSil silica media. Its strategy is to replace imported media in China's growing biologics and peptide manufacturing sector and to offer media together with chromatography instruments, supported by acquisitions of instrument makers and expansion into export markets.
Competitor Dashboard
The dashboard below rates each profiled company on four qualitative parameters: breadth and depth of its chromatography resin portfolio, geographic presence, strategic alliances and partnerships, and industry experience.
Porter's Five Forces framework is used to assess the competitive intensity and attractiveness of the chromatographic separation resins market. Each force is rated High, Medium or Low based on its influence on industry profitability.
Threat of New Entrants: Low
Technical barriers: Proprietary base matrix technologies, ligand chemistries and manufacturing know-how require long development cycles and significant capital investment.
Regulatory lock-in: Resins specified in approved biologic processes are rarely changed, limiting access to the commercial installed base for new suppliers.
Customer qualification: Biopharmaceutical customers require extensive documentation, supply track records and quality audits before qualifying a new resin supplier.
Bargaining Power of Suppliers: Medium
Specialised inputs: High-purity agarose and recombinant ligands are available from a limited number of qualified sources, and many leading resin manufacturers have vertically integrated ligand production.
Commodity inputs: Synthetic monomers, solvents and packaging materials are widely available, limiting supplier leverage for these inputs.
Traceability requirements: Change control and animal-origin-free requirements increase switching costs for resin manufacturers in relation to key raw material suppliers.
Bargaining Power of Buyers: Medium
Concentrated large buyers: Large biopharmaceutical companies and CDMOs purchase significant volumes and can negotiate long-term supply agreements and volume pricing.
Switching constraints: Once a resin is embedded in a commercial process, buyers face high switching costs, which reduces their leverage for established products.
Price-sensitive segments: Biosimilar producers, food processors and academic users are more price-sensitive and more willing to qualify alternative suppliers.
Threat of Substitutes: Medium
Membranes and monoliths: Membrane adsorbers and monolithic columns are substituting packed-bed resins in selected flow-through polishing and large-biomolecule applications.
Non-chromatographic methods: Precipitation, crystallisation and extraction techniques are under investigation but have limited commercial adoption in biopharmaceutical processes.
Limited substitution for capture: Affinity capture with bead-based resins remains the industry standard for monoclonal antibodies, constraining substitution in the largest value pool.
Intensity of Competitive Rivalry: High
Innovation-led competition: Leading suppliers compete on binding capacity, alkaline stability, lifetime and selectivity, with frequent product launches.
Emerging regional challengers: Manufacturers in China and other Asian markets are expanding portfolios and competing on price and local service.
Bundled offerings: Large life science groups compete through integrated portfolios spanning resins, columns, systems and services.
Threat of New Entrants: Low; High technical, regulatory and qualification barriers protect established suppliers.
Bargaining Power of Suppliers: Medium; Specialised inputs are concentrated, but vertical integration and commodity inputs limit leverage.
Bargaining Power of Buyers: Medium; Large buyers negotiate volume terms, but process lock-in raises switching costs.
Threat of Substitutes: Medium; Membranes and monoliths are gaining share in selected steps, while affinity capture remains resin-based.
Intensity of Competitive Rivalry: High; Innovation-led competition among global leaders and rising regional challengers.
